Literature DB >> 18952587

IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK.

Oren J Becher1, Katia M Peterson, Soumen Khatua, Maria R Santi, Tobey J MacDonald.   

Abstract

To identify targets critical to malignant childhood astrocytoma, we compared the expression of receptor tyrosine kinase- associated genes between low-grade and high-grade pediatric astrocytomas. The highest differentially overexpressed gene in high-grade astrocytoma is insulin-like growth factor- binding protein-2 (P = .0006). Immunohistochemistry confirmed overexpression of insulin-like growth factor-binding protein-2 protein (P = .027). Insulin-like growth factor- binding protein-2 stimulation had no effect on astrocytoma cell growth and migration, and minimally inhibited insulin-like growth factor-1-mediated migration, but not insulin-like growth factor-2-mediated migration. However, insulin-like growth factor-binding protein-2 stimulation significantly upregulated the major DNA repair enzyme gene, DNA-PKcs, and induced DNA-dependent protein kinase catalytic subunit protein expression in a time-dependent and dose-dependent manner, whereas insulin-like growth factor-1 had no effect. DNA-PKcs is also highly overexpressed by high-grade astrocytomas. These findings suggest insulin-like growth factor-binding protein-2 plays a role in astrocytoma progression by promoting DNA-damage repair and therapeutic resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18952587      PMCID: PMC3674842          DOI: 10.1177/0883073808321766

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  46 in total

Review 1.  Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?

Authors:  A Hoeflich; R Reisinger; H Lahm; W Kiess; W F Blum; H J Kolb; M M Weber; E Wolf
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

2.  Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas.

Authors:  H Hirano; M B Lopes; E R Laws; T Asakura; M Goto; J E Carpenter; L R Karns; S R VandenBerg
Journal:  Neuro Oncol       Date:  1999-04       Impact factor: 12.300

3.  In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade.

Authors:  M W Elmlinger; M H Deininger; B S Schuett; R Meyermann; F Duffner; E H Grote; M B Ranke
Journal:  Endocrinology       Date:  2001-04       Impact factor: 4.736

4.  Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease.

Authors:  T J MacDonald; K M Brown; B LaFleur; K Peterson; C Lawlor; Y Chen; R J Packer; P Cogen; D A Stephan
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

Review 5.  DNA-dependent protein kinase complex: a multifunctional protein in DNA repair and damage checkpoint.

Authors:  Suk-Hee Lee; Chung-Hui Kim
Journal:  Mol Cells       Date:  2002-04-30       Impact factor: 5.034

6.  Insulin-like growth factor I stimulates motility in human neuroblastoma cells.

Authors:  G E Meyer; E Shelden; B Kim; E L Feldman
Journal:  Oncogene       Date:  2001-11-08       Impact factor: 9.867

7.  Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.

Authors:  T Sung; D C Miller; R L Hayes; M Alonso; H Yee; E W Newcomb
Journal:  Brain Pathol       Date:  2000-04       Impact factor: 6.508

8.  Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort.

Authors:  I F Pollack; S D Finkelstein; J Burnham; E J Holmes; R L Hamilton; A J Yates; J L Finlay; R Sposto
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

9.  Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility.

Authors:  Xihong Zhang; Douglas Yee
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

10.  Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes.

Authors:  Hua Wang; Huamin Wang; Weiping Shen; Helen Huang; Limei Hu; Latha Ramdas; Yi-Hong Zhou; Warren S-L Liao; Gregory N Fuller; Wei Zhang
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

View more
  11 in total

1.  IGFBP-2 - taking the lead in growth, metabolism and cancer.

Authors:  Steven W Yau; Walid J Azar; Matthew A Sabin; George A Werther; Vincenzo C Russo
Journal:  J Cell Commun Signal       Date:  2015-01-25       Impact factor: 5.782

2.  Bioactive insulin-like growth factor-I in obesity.

Authors:  J Frystyk; D J Brick; A V Gerweck; A L Utz; K K Miller
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

Review 3.  IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.

Authors:  Xiaofeng Yao; Shanshan Sun; Xuan Zhou; Wenyu Guo; Lun Zhang
Journal:  Tumour Biol       Date:  2015-12-09

4.  IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.

Authors:  Haibo Lu; Li Wang; Wen Gao; Jieru Meng; Bingbing Dai; Shuhong Wu; John Minna; Jack A Roth; Wayne L Hofstetter; Stephen G Swisher; Bingliang Fang
Journal:  Mol Cancer Ther       Date:  2013-10-15       Impact factor: 6.261

5.  IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.

Authors:  Amy L Myers; Lin Lin; Derek J Nancarrow; Zhuwen Wang; Daysha Ferrer-Torres; Dafydd G Thomas; Mark B Orringer; Jules Lin; Rishindra M Reddy; David G Beer; Andrew C Chang
Journal:  Oncotarget       Date:  2015-09-22

6.  IGFBP2 potentiates nuclear EGFR-STAT3 signaling.

Authors:  C Y Chua; Y Liu; K J Granberg; L Hu; H Haapasalo; M J Annala; D E Cogdell; M Verploegen; L M Moore; G N Fuller; M Nykter; W K Cavenee; W Zhang
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

7.  Long non-coding RNA HOTAIR promotes cell migration by upregulating insulin growth factor-binding protein 2 in renal cell carcinoma.

Authors:  Hiromichi Katayama; Keiichi Tamai; Rie Shibuya; Mao Nakamura; Mai Mochizuki; Kazunori Yamaguchi; Sadafumi Kawamura; Tatsuo Tochigi; Ikuro Sato; Takamasa Okanishi; Kunie Sakurai; Wataru Fujibuchi; Yoichi Arai; Kennichi Satoh
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

8.  Hyperglycemia Promotes TMPRSS2-ERG Gene Fusion in Prostate Cancer Cells via Upregulating Insulin-Like Growth Factor-Binding Protein-2.

Authors:  Jeff M P Holly; Jessica Broadhurst; Rehanna Mansor; Amit Bahl; Claire M Perks
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-06       Impact factor: 5.555

9.  Therapeutic Effect of Epigallocatechin-3-gallate (EGCG) and Silibinin on ATM Dynamics in Prostate Cancer Cell Line LNCaP.

Authors:  Ammad Ahmad Farooqi; Qaisar Mansoor; Muhammad Ismail; Shahzad Bhatti
Journal:  World J Oncol       Date:  2011-01-01

10.  Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival.

Authors:  Chengcheng Guo; Haibo Lu; Wen Gao; Li Wang; Kaihua Lu; Shuhong Wu; Apar Pataer; Maosheng Huang; Randa El-Zein; Tongyu Lin; Jack A Roth; Reza Mehran; Wayne Hofstetter; Stephen G Swisher; Xifeng Wu; Bingliang Fang
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.